StreetInsider.com News Articles

Biomea Fusion doses first patient in obesity combo drug study

Thu, 13 Aug 2026 07:02:31 -0400

Biomea Fusion, Inc. (Nasdaq: BMEA) announced that the first participant has been dosed in a new arm of the OPAL platform research study, evaluating its investigational compound icovamenib in combination with low-dose semaglutide in people who are overweight or obese without type 2 diabetes.

The study arm is being conducted in collaboration with the University of Leicester and the Leicester Diabetes Centre, led by Professor Dame Melanie Davies and Professor Thomas Yates, alongside the NIHR Biomedical Research Centre Leicester.

The randomized, double-blind study arm plans to enroll 64 participants split equally between two groups: one receiving icovamenib (100mg, once daily for 12

Biomea Fusion doses first patient in obesity combo drug study

Thu, 13 Aug 2026 07:02:31 -0400

The randomized, double-blind study arm plans to enroll 64 participants split equally between two groups: one receiving icovamenib (100mg, once daily for 12

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Thu, 13 Aug 2026 07:00:00 -0400

• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes

SAN CARLOS, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that the first participant has been dosed in a new arm of the ongoing platform research study, Investigating and Optimizing Physical Function with Weight Loss: A Multi-Arm Open Label Adaptive Platform Trial (“OPAL”). The study is being conducted in collaboration with

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Thu, 13 Aug 2026 07:00:00 -0400

Citi opens 90-day Positive catalyst watch on Biomea Fusion

Tue, 11 Aug 2026 04:48:03 -0400

Citi analyst Yigal Nochomovitz reiterated a Buy rating and $7.00 price target on Biomea Fusion Inc. (NASDAQ: BMEA).

The analyst noted that timelines for icovamenib's Phase 2 26-week Type 2 diabetes data have been pushed back due to enrollment pace. Data from the COVALENT-211 trial in insulin-deficient patients is now expected in the first quarter of 2027, moved from the fourth quarter of 2026. Data from the COVALENT-212 trial, targeting patients uncontrolled on GLP-1-based therapy, is now expected in the second quarter of 2027, also shifted from the fourth quarter of 2026.

Management has described the COVALENT-211 study as a key milestone,

Biomea Fusion, Inc. (BMEA) Tops Q2 EPS by 9c

Wed, 05 Aug 2026 18:18:31 -0400

Biomea Fusion, Inc. (NASDAQ: BMEA) reported Q2 EPS of ($0.12), $0.09 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Biomea Fusion, Inc. (BMEA) click here.

Form 10-Q Biomea Fusion, Inc. For: Jun 30

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874233.html

Form 10-Q Biomea Fusion, Inc. For: Jun 30

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874233.html

Form 8-K Biomea Fusion, Inc. For: Aug 05

Wed, 05 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26874152.html

Form 8-K Biomea Fusion, Inc. For: Aug 05

Wed, 05 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26874152.html

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Wed, 05 Aug 2026 16:05:00 -0400

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists (“GLP-1 RA”)-based therapy; data expected in the second quarter of 2027
Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026
Research collaboration initiated with the University of Leicester to evaluate icovamenib in combination with semaglutide in

JPMorgan analysts name top short ideas for third quarter 2026

Fri, 10 Jul 2026 11:12:30 -0400

Investing.com -- JPMorgan released its list of top short ideas for the third quarter of 2026, featuring selections from its highest-ranked U.S. equity research analysts across multiple sectors.
The list includes 24 companies spanning capital goods, consumer, energy, financials, healthcare, materials, media and telecom, and technology sectors. Each selection represents what the bank's analysts view as their most compelling structural and tactical short positions.
In the technology sector, Intel Corp (NASDAQ:INTC) received an underweight rating from analyst Harlan Sur, while Wix.com Ltd (NASDAQ:WIX) was rated underweight by Alexei Gogolev.
The healthcare sector features four companies on the list, including Moderna Inc (NASDAQ:MRNA), rated

JPMorgan analysts name top short ideas for third quarter 2026

Fri, 10 Jul 2026 11:12:30 -0400

Investing.com -- JPMorgan released its list of top short ideas for the third quarter of 2026, featuring selections from its highest-ranked U.S. equity research analysts across multiple sectors.
The list includes 24 companies spanning capital goods, consumer, energy, financials, healthcare, materials, media and telecom, and technology sectors. Each selection represents what the bank's analysts view as their most compelling structural and tactical short positions.
In the technology sector, Intel Corp (NASDAQ:INTC) received an underweight rating from analyst Harlan Sur, while Wix.com Ltd (NASDAQ:WIX) was rated underweight by Alexei Gogolev.
The healthcare sector features four companies on the list, including Moderna Inc (NASDAQ:MRNA), rated

JPMorgan analysts name top short ideas for third quarter 2026

Fri, 10 Jul 2026 11:12:30 -0400

Investing.com -- JPMorgan released its list of top short ideas for the third quarter of 2026, featuring selections from its highest-ranked U.S. equity research analysts across multiple sectors.
The list includes 24 companies spanning capital goods, consumer, energy, financials, healthcare, materials, media and telecom, and technology sectors. Each selection represents what the bank's analysts view as their most compelling structural and tactical short positions.
In the technology sector, Intel Corp (NASDAQ:INTC) received an underweight rating from analyst Harlan Sur, while Wix.com Ltd (NASDAQ:WIX) was rated underweight by Alexei Gogolev.
The healthcare sector features four companies on the list, including Moderna Inc (NASDAQ:MRNA), rated